Targets › PS
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on PS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bexion Pharmaceuticals | BXQ-350 Saposin C (SapC) combined with phospholipid dioleoylphosphatidyl-serine (DOPS) forming a p | PS | Phase 1 | Metastatic Colorectal Carcinoma | Nov 2026 |
Metastatic Colorectal Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.